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Background: In resource-poor areas of China and India, the cardiovascular disease burden is high, but availability of
and access to quality healthcare is limited. Establishing a management scheme that utilizes the local infrastructure
and builds healthcare capacity is essential for cardiovascular disease prevention and management. The study aims
to develop, implement, and evaluate the feasibility and effectiveness of a simplified, evidence-based cardiovascular
management program delivered by community healthcare workers in resource-constrained areas in Tibet, China
and Haryana, India.
Methods/design: This yearlong cluster-randomized controlled trial will be conducted in 20 villages in Tibet and 20 villages
in Haryana. Randomization of villages to usual care or intervention will be stratified by country. High cardiovascular disease
risk individuals (aged 40 years or older, history of heart disease, stroke, diabetes, or measured systolic blood pressure of
160 mmHg or higher) will be screened at baseline. Community health workers in the intervention villages will be trained to
manage and follow up high-risk patients on a monthly basis following a simplified ‘2 + 2’ intervention model involving two
lifestyle recommendations and the appropriate prescription of two medications. A customized electronic decision support
system based on the intervention strategy will be developed to assist the community health workers with patient
management. Baseline and follow-up surveys will be conducted in a standardized fashion in all villages. The primary
outcome will be the net difference between-group in the proportion of high-risk patients taking antihypertensive
medication pre- and post-intervention. Secondary outcomes will include the proportion of patients taking aspirin and
changes in blood pressure. Process and economic evaluations will also be conducted.
Discussion: To our knowledge, this will be the first study to evaluate the effect of a simplified management program
delivered by community health workers with the help of electronic decision support system on improving the health
of high cardiovascular disease risk patients. If effective, this intervention strategy can serve as a model that can be
implemented, where applicable, in rural China, India, and other resource-constrained areas.
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Trial registration: The trial was registered in the clinicaltrials.gov database on 30 December, 2011 and the registration
number is NCT01503814.
Keywords: Cardiovascular diseases prevention and control, Research design, Developing countries, Rural population,
Community health workers, Risk reduction, Electronic decision support systemBackground
An estimated 17 million people die of cardiovascular disease
(CVD) each year with over 80% of these deaths occurring in
low and middle-income countries [1]. Resource-poor areas
in China and India, where CVD is already the leading cause
of death, confront a rising disease burden with a strained
healthcare system often inadequately equipped to deal with
these problems [2-4]. Many of the risk factors strongly asso-
ciated with CVD, including high blood pressure, tobacco
use, and poor diet are among the top risk behaviors in these
countries [5,6]. For example, in studies assessing hyperten-
sion in rural areas of Tibet, China, up to 14.9% of the popu-
lation aged 15 years or older was found to be hypertensive,
with some townships having rates as high as 55.9% in adults
40 years old and above [7,8]. The overall hypertension rate
was found to be just as high in Haryana, India, with the
urban slums of Faridabad District, Haryana similarly affected
at 16.5% [9,10]. Despite these high rates of hypertension, the
number of patients receiving antihypertensive therapy in
these areas remains low, and way below the averages seen in
urban areas [7,11].
There are many well-established interventions such as
lifestyle modification of known risk factors and effective,
low-cost medications that can help avert the CVD bur-
den in these economic and healthcare resource limited
settings [12-21]. One particularly cost-effective approach
is to identify and manage individuals at high cardiovas-
cular disease risk in order to prevent or delay events
[22-28]. This method has been applied and implemented
in the Rural Andhra Pradesh Cardiovascular Prevention
Study in India and the China Rural Health Initiative in
northern China [29-31].
Community Health Workers (CHWs) are the mem-
bers who received basic professional training to provide
health and medical care for the community. Involvement
of CHWs in disadvantaged populations has resulted in a
significant improvement in accessing healthcare facil-
ities, screening disease, monitoring community mem-
bers’ health status and adherence to treatment [32-35].
Task-shifting to CHWs has been proven as a cost-
effective and sustainable approach in chronic disease
prevention and control, particularly in those areas with
limited economic and healthcare resources [36]. More
recently, with the aid of mobile phones, studies have
shown a significant reduction in CHW training time,disease screening time and an enhanced user satisfaction
[37]. A recent systematic review also shows that mobile
phone based technology in low and middle income
countries positively impacts the chronic disease man-
agement and its associated clinical outcomes [38].
Simplifying and extending the high-risk intervention
strategy to suit areas with high CVD burden, but more
limited economic and healthcare resources will be essen-
tial to addressing this problem in an effective and afford-
able way in these areas. China and India are two largest
developing countries in the world that face similar chal-
lenges in terms of the burden of CVD and resource con-
straints in tackling these challenges. Yet, there are also
many differences in the healthcare systems, socio-
economical environment and ethno-cultural customs
that will make conducting a joint study illuminating and
fruitful.
Therefore, we have designed a study to develop and
evaluate the effects of implementing, in resource-scarce
settings, a highly simplified but guideline-based program
for cardiovascular management by CHWs with the aid
of electronic decision support system in rural China and
India (the SimCard study). This paper describes the re-
search design and the rationale of the study.
Methods/design
The SimCard study is a cluster-randomized controlled
interventional trial to be conducted in rural areas of
Tibet, China and Haryana, India. The design, implemen-
tation and reporting of the study follow recommenda-
tions from CONSORT statement on cluster-randomized
trials [39]. The trial was registered in the clinicaltrials.
gov database on 30 December, 2011 and the registration
number is NCT01503814. The study protocol received
ethics approval from the institutional review boards at
Peking University Health Sciences Center, China, the
Public Health Foundation of India, India, and Duke Uni-
versity, USA. Informed consent will be obtained from
each study participant.
Study sites
Two counties in the Tibet autonomous region located
in Southwest China – Gongbujiangda and Linzhou -
and one tehsil - Ballabgarh in Faridabad District from
Haryana State in northwestern India will participate in
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take part in this study based on the site selection criteria
of (1) high CVD burden, (2) limited healthcare resources,
(3) having available existing CHWs or qualified candidates
who can be trained to fulfill that role, and (4) local govern-
ment support. A total of 40 villages will be recruited
across the two countries, 20 in each country.
Randomization
In each country, villages will be randomized to receive the
intervention or usual care. Randomization will be stratified
by country. In China, all selected villages will be randomized
by a 1:1 ratio to the intervention and control group with
stratification by county and township (the administrative
unit managing the villages). In India, randomization will not
be stratified by any geographical locations. Randomization
in both countries will be conducted by a study staff not in-
volved in the intervention through a central computerized
process. Group allocation will be concealed until after the
baseline data collection is completed.
Study population
Participants at CVD high risk will be eligible for study
enrollment. In this study, ‘high-risk’ is defined as older
age (40 years old and above) with a history of any of the
following conditions: coronary heart disease, stroke (ische-
mic, hemorrhagic, or unknown/unspecified type), diabetes
mellitus, and/or having a systolic blood pressure ≥160 mmHg
at two different time points measured in the same day dur-
ing the baseline survey.
Exclusion criteria include having CVD-related compli-
cations that cannot be managed in a primary care set-
ting, having a malignancy or life-threatening disease;
individuals who are bed-ridden, currently participating
in any other clinical trials, unable to stay in the village
longer than 8 months in a year, and planning to move in
the next year.
Screening
Before the start of the baseline data collection, a survey
will be conducted in all participating villages to screen
for high-risk individuals. All village residents 40 years
and above will be invited to participate in the survey,
which will include a brief questionnaire on disease his-
tory and measuring blood pressure twice. All high-risk
individuals screened out through this process according
to the definition described above, a target minimum of




The intervention scheme adapts and simplifies inter-
national and applicable national clinical guidelines forhypertension and cardiovascular disease management for
use by local CHWs to manage cardiovascular high-risk
patients in an easily implementable, low cost, and medic-
ally effective way [23,40]. Local CHWs will be trained to
provide basic monthly follow-up care to identified high-
risk patients, and refer them to higher level healthcare
facilities when necessary. The intervention strategy con-
sists of the following:
‘2 + 2’ intervention model
Taking into consideration the local health behaviors and
resources, a simplified management model is devised
that focuses on two therapeutic lifestyle recommenda-
tions (smoking cessation and salt reduction) and the ap-
propriate prescription of two types of accessible, highly
effective, generally safe, and low-cost drugs (blood pres-
sure lowering drugs and aspirin) [41-46]. In India, as
stipulated by the ethic committee, the drugs used in the
intervention arm will be also made available to the pri-
mary care facilities serving the control villages. Coined
the “2 + 2” intervention model, the scheme targets two
prevalent risk behaviors with established relationships to
CVD while providing instruction on the prescription of
two types of basic drugs that have well-documented effects
on CVD risk reduction. All individuals in the intervention
group will receive therapeutic lifestyle recommendations
when applicable, but depending on each individual’s med-
ical situation may be prescribed both, one, or none of the
two types of drugs. These interventions will be delivered
by CHWs and they will provide monthly follow-up to all
high-risk patients under their care.
Systematic training of local CHWs
Enhancing the capacity of local CHWs through system-
atic training is a key feature of the intervention model.
Training of local CHWs in the intervention group will
consist of an initial training on the intervention proto-
col, including education on the targeted CVD lifestyle
risk factors and the medications being utilized, followed
by refresher training about 1–3 months after the inter-
vention begins. Only CHWs who pass the initial evalu-
ation examination can take part in implementing the
intervention. After the training, CHWs will be provided
with a list of high-risk individuals screened out at base-
line for them to contact and manage according to the
protocol.
In Tibet, China, “village doctors” who are not physi-
cians but have basic professional training and can pre-
scribe medications will be chosen to be the CHWs to
implement this management plan. In rural India, local
women will be recruited and trained to be the study’s
CHWs. Because the Indian CHWs have no prior medical
experience, they will be partnered with licensed physi-
cians from nearby primary health care centers who are
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*: Not covered in Tibet, China site.
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CHWs’ regular assessments of their assigned high-risk
patients.
Electronic decision support
An electronic decision support (EDS) component will be
incorporated in this study to assist the CHWs on the fol-
low up and management of their high-risk patients dur-
ing the one-year intervention period. The EDS system is
a smartphone or tablet-based android application that
will be developed and pilot tested based on the ‘2 + 2’
intervention model and consists of prompts regarding
the patient’s medical history, new conditions, medication
usage, current lifestyle habits, blood pressure, and the
appropriateness for prescribing any of the target medica-
tions. The follow-up records entered into the device can
be easily uploaded by CHWs to a central server to gen-
erate performance indicators and provide feedback to
help improve the quality of care. In India, the EDS sys-
tem has a desktop component for the use of physicians
to prescribe drugs in the intervention arm.
Performance feedback
Tiered monetary payments based on key performance
indicators will be given to CHWs on a recurring basis.
Examples of key performance indicators include the
number and percentage of high-risk individuals receiving
regular follow-up, lifestyle advices, and medications.
Control
Villages in the control group will continue their usual
practices without any of the above mentioned interven-
tions. Usual practices will include any other government
or project-initiated lifestyle, hypertension or cardiovas-
cular management programs.
Outcome evaluation
Baseline and post-intervention survey
The outcome evaluation for this study will be derived
from data collected from the baseline survey and post-
intervention follow-up survey of all eligible and consent-
ing high-risk patients in the intervention and control
villages. Both survey questionnaires will be identical, and
include information on patient’s demographics, disease
history, lifestyle behaviors, medication use, primary
healthcare services utilization, hospitalizations, and med-
ical care related expenses in the past year. Height,
weight, waist circumference, and blood pressure will be
measured at that time of the survey. Surveys in both
countries will be conducted by trained personnel accord-
ing to the same standardized operating procedures. The
questionnaires used in China and India will be kept
nearly identical except for a few variations to fit the cul-
tural context and target the specific lifestyles of the twopeoples in these countries such as different types of to-
bacco use (See Table 1 for survey indicators).
The primary outcome will be the net difference between
the intervention and control groups in the pre- and post-
intervention change in the proportion of high-risk individ-
uals treated with anti-hypertensive medication, obtained
through the two surveys described above. This process in-
dicator is chosen for its close association with the inter-
vention scheme, effect on lowering high blood pressure,
and its excellent power.
A number of secondary outcomes will also be evaluated,
including the net difference between the intervention and
control groups in the pre- and post-intervention change
in the proportion of high-risk individuals treated with as-
pirin, the net difference in mean blood pressure from
baseline to follow-up in high-risk individuals between the
intervention and control villages, as well as hypertension
awareness, treatment, and control rates. Awareness of
modifiable lifestyle risk behaviors will also be assessed,
specifically on the proportion of high-risk individuals
aware of the harms of smoking and consumption of a
high salt diet. Finally, the proportion of high-risk indi-
viduals receiving five or more follow-up visits from
CHWs will also be calculated.
Sample size
Key underlying assumptions for this study are that
there will be 20 intervention villages and 20 control
villages with 50 consenting high-risk patients in each
village and an estimated total of 2,000 high-risk indi-
viduals, an intra-cluster correlation coefficient (ICC) of
0.01 or 0.02 [36,47], and two-sided alpha of 0.05. For
the primary outcome, assuming the proportion of anti-
hypertensive medication prescriptions in the control
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it to be <10% in the target study sites), the power to
detect a 10% difference in the primary outcome of
anti-hypertensive medication use is excellent (>90%)
with an ICC of 0.01, and similarly high with an ICC of
0.02. Assuming a standard deviation of change in sys-
tolic blood pressure of 15 mmHg among the high-risk
individuals, the power to detect a 3 mmHg net differ-
ence in this secondary outcome between the interven-
tion and control group pre-post differences will be
>90% with an ICC of 0.01 (>90% as well if ICC = 0.02).
Statistical analysis
All analyses will be conducted at individual level accord-
ing to intention-to-treat principles, and take into ac-
count the stratification design and cluster effects. For
the primary outcome, anti-hypertensive medication use,
log-binomial models with random effects for villages to
account for clustering and random effects for intercept
to account for the pre-post correlations within individ-
uals and a fixed effect for country to account for the
stratified study design will be used. Other than the main
effect from intervention and time, an interaction term
between intervention and time will be added in the
model to test if the slope of the pre-post changes differs
by intervention or control group. To account for the
heterogeneity between two countries, the two-way inter-
action of the country variable with intervention and time
will be included into the above models. In the case of
significant interaction existing, the separate analysis by
country will be conducted afterward. The net effect from
intervention will be reported as difference-in-difference
of proportions together with model-based 95% confi-
dence intervals obtained by transforming back from
models. For continuous outcomes, such as systolic blood
pressure, similar strategies will be adopted but linear
models instead of log-binomial models will be used.
Some adjusted analysis will also be performed to account
for potential unbalanced baseline information. Other
pre-specified subgroup will include analyses by sex and
age (40–59 vs. 60 years or older) using similar strategy
for the country variable.
Process and economic evaluation
Process evaluation will be conducted at the end of the
intervention program to investigate the extent to which
the intervention has been implemented as designed, and
to identify the facilitators and barriers to the implemen-
tation of the intervention program at each level of the
study. We will conduct face-to-face, semi-structured in-
terviews by independent interviewers. Interviewees in-
clude the CHWs, high-risk individuals in the selected
villages, local project administrators, and government offi-
cials. A standardized interview guideline will be developedthat contains a mixture of close- and open-ended ques-
tions. All interviews will be audio-recorded, transcribed
and analyzed using a qualitative descriptive interpretive
approach combing thematic content analysis and constant
comparison methods facilitated by QSR NVIVO 10.0 data
management software. The economic evaluation will help
determine the economic feasibility of expanding such an
intervention using data collected on healthcare services
usage and medication use as obtained from the follow-up
surveys.
Discussion
CVD is a global problem that affects developed and de-
veloping countries alike. Areas with constrained eco-
nomic or healthcare resources face an even tougher
challenge as the awareness of CVD is lacking and
trained healthcare professionals are limited. The Sim-
Card study in China and India aims to evaluate a simpli-
fied, multifaceted, and innovative intervention scheme
for CVD prevention and control in resource-scarce set-
tings. To the best of our knowledge, SimCard is the first
study to incorporate an EDS system delivered by the
CHWs for CVD management in these two countries.
The findings of the study will provide evidence on the
feasibility, acceptability and effectiveness of a simplified
yet guideline-based intervention program delivered by
the CHWs in resource constrained areas.
The study design aims to maximize the feasibility of
the intervention through a simplified culturally-tailored
CVD prevention and management plan based on the
guidelines. Despite there being well-established national
guidelines and policies on effective strategies to prevent
and control CVD in China and India, its uptake into
routine medical care remains very limited in resource
constrained areas. This is primarily due to the complex-
ity of the guideline, the lack of awareness of the guide-
lines by the CHWs and CHW’s limited capacity to
implement the guidelines. CHWs who will be utilizing
the simplified management scheme descried in this study
will be thoroughly trained and tested for competency on
the indications, contraindications and side effects of the
medications. CHWs will also be trained to provide thera-
peutic lifestyle recommendations as applicable. CHWs will
be provided incentives based on the key performance indi-
cators such as the regular follow-up rate, the percentage
of high-risk individuals receiving lifestyle advices and
other measurements.
The intervention is also designed to be innovative. By
2013, there were over 2 billion mobile phone subscribers
in China and India [48]. This accounts for a staggering
one third of the world’s mobile users [48]. Smartphones
and tablets with their advanced multimedia capability
and connectivity to the internet are rapidly expanding in
the developing countries’ market. These mobile devices
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the internet and for example, China represents 22% of
the global smartphone subscribers [49]. China has sur-
passed the U.S.A. to become the world’s top country for
active Android and iOS users. Given the near ubiquity
of mobile phones and the exponential growth of smart
phones and tablets in Chinese and Indian markets, these
devices represent one of the few hardware products avail-
able with the potential to transform the delivery of health
care. There is growing evidence showing smartphone or
tablet based EDS system can improve patient care in both
developed and developing countries [38,50]. Therefore, we
incorporate the smartphone or tablet based EDS system
into the intervention aiming to help the CHWs better
follow-up and manage their high CVD risk patients.
Such a study is needed in both rural China and India
where the prevalence of hypertension and CVD has been
increasing rapidly and has reached epidemic propor-
tions. The healthcare systems in both countries by and
large are still acute care-oriented and ill-equipped to
tackle these challenges. Shifting to and sharing of certain
preventive tasks with CHWs is one important strategy
that both countries need to evaluate for effectiveness
and future scale-up if possible. In addition, implementa-
tion of the intervention needs to adapt to local contexts
in order to be successful. China and India (in our study,
Tibet and Haryana, respectively) possess distinctive fea-
tures in primary healthcare delivery models, local cultural
values and practices, and even regulations and governance
of research studies. We anticipate this joint study in two
countries will shed light on how this adaptation process
can take place and how these differences may influence
the results of the study. For example, in Tibet, Tibetan
medicine is a widely believed system that can sometimes
be at odds with Western medicine. In north India, women
do not generally interact with non-family men. This gen-
der relations issue will potentially pose some constraints
to the Indian CHWs, who will all be female, in carrying
out the management plan among male high-risk patients,
which can be addressed with involvement of women from
the patient’s household. Many strategies and standardized
operation procedures will be in place to ensure the quality
of the implementation of the study protocol while taking
into consideration differences between the two countries.
The burden of non-communicable chronic diseases is
rapidly rising, but many areas lack the economic and
healthcare resources to effectively deal with these wide-
spread health problems. While evidence-based national
and international guidelines on managing chronic condi-
tions such as hypertension, coronary heart disease, and
stroke are well-established, cost-effective approaches suit-
able for adoption in resource-constrained settings have
not been adequately investigated. The SimCard study aims
to address the highly prevalent problem of CVD in theseremote and resource- limited areas that have not re-
ceived much attention so far. The results of the study
are expected both to advance scientific knowledge and
to provide translational evidence necessary for sound
policy making to address the CVD problem in these
settings, in China, India, and where applicable, to other
countries.
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